WO2000023060A8 - Method of treating immunological disorders mediated by t-lymphocytes - Google Patents

Method of treating immunological disorders mediated by t-lymphocytes

Info

Publication number
WO2000023060A8
WO2000023060A8 PCT/US1999/024371 US9924371W WO0023060A8 WO 2000023060 A8 WO2000023060 A8 WO 2000023060A8 US 9924371 W US9924371 W US 9924371W WO 0023060 A8 WO0023060 A8 WO 0023060A8
Authority
WO
WIPO (PCT)
Prior art keywords
lymphocytes
immunological disorders
disorders mediated
treating immunological
treating
Prior art date
Application number
PCT/US1999/024371
Other languages
French (fr)
Other versions
WO2000023060A2 (en
WO2000023060A3 (en
Inventor
David Erickson
Peter M Grob
Ann F Hoffman
Thomas C Warren
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Priority to AU13170/00A priority Critical patent/AU1317000A/en
Publication of WO2000023060A2 publication Critical patent/WO2000023060A2/en
Publication of WO2000023060A3 publication Critical patent/WO2000023060A3/en
Publication of WO2000023060A8 publication Critical patent/WO2000023060A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of soluble epoxide hydrolase inhibitors in the treatment of T-lymphocyte mediated immunological disorders is described either as monotherapies or as part of combination therapies for such disorers.
PCT/US1999/024371 1998-10-20 1999-10-19 Method of treating immunological disorders mediated by t-lymphocytes WO2000023060A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13170/00A AU1317000A (en) 1998-10-20 1999-10-19 Method of treating immunological disorders mediated by t-lymphocytes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10487598P 1998-10-20 1998-10-20
US60/104,875 1998-10-20

Publications (3)

Publication Number Publication Date
WO2000023060A2 WO2000023060A2 (en) 2000-04-27
WO2000023060A3 WO2000023060A3 (en) 2000-09-08
WO2000023060A8 true WO2000023060A8 (en) 2001-03-01

Family

ID=22302869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024371 WO2000023060A2 (en) 1998-10-20 1999-10-19 Method of treating immunological disorders mediated by t-lymphocytes

Country Status (2)

Country Link
AU (1) AU1317000A (en)
WO (1) WO2000023060A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831082B2 (en) 2001-06-29 2004-12-14 Boehringer Ingelheim Pharmaceuticals, Inc. Method of using soluble epoxide hydrolase inhibitors
JP2007532484A (en) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Method for alleviating nephropathy using an inhibitor of soluble epoxide hydrolase and epoxyeicosanoids
US20050222252A1 (en) * 2004-03-31 2005-10-06 The Regents Of The University Of California Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
WO2006133257A2 (en) 2005-06-06 2006-12-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
CA2619768A1 (en) 2005-08-19 2007-02-22 The Regents Of The University Of California Use of seh inhibitors as analgesics
WO2007067836A2 (en) * 2005-12-05 2007-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
EP2091542A1 (en) 2006-12-18 2009-08-26 F. Hoffmann-Roche AG Novel use of inhibitors of soluble epoxide hydrolase
EP2178534A4 (en) 2007-07-17 2011-03-30 Merck Sharp & Dohme Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US8809552B2 (en) 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
US10383835B2 (en) * 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US20160008342A1 (en) 2014-06-16 2016-01-14 The Regents Of The University Of California Methods of improving cell-based therapy
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
EP3584236A1 (en) 2018-06-20 2019-12-25 Universitat de Barcelona Polycyclic compounds soluble epoxide hydrolase inhibitors
EP4063348A1 (en) 2021-03-24 2022-09-28 Universitat de Barcelona Compounds as soluble epoxide hydrolase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
JP2002516909A (en) * 1998-06-05 2002-06-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Substituted 1- (4-aminophenyl) pyrazoles and their use as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2000023060A2 (en) 2000-04-27
WO2000023060A3 (en) 2000-09-08
AU1317000A (en) 2000-05-08

Similar Documents

Publication Publication Date Title
WO2000023060A8 (en) Method of treating immunological disorders mediated by t-lymphocytes
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
AU2305295A (en) Use of serotonin antagonists (5HT3) for treating fibro myalgia
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
CA2070254A1 (en) Thrombin inhibitors
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
PL330782A1 (en) Method of treating carcinoma using the inhibitors of naaladase
ZA966240B (en) Methods for treatment of allergic asthma.
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
AU6256996A (en) Use of vitamin D4 derivatives for treating skin disorders
AU2001273399A1 (en) Method for treating circulatory disorders with acoustic waves
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU4726797A (en) Prophylactic/remedial agent
AU2982495A (en) Heterocycle-condensed morphinoid derivatives
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
EP1385993B8 (en) Method of detecting and treating tuberous sclerosis complex associated disorders
AU2002252134A1 (en) Methods of treating irritable bowel syndrome and functional dyspepsia
AU2417995A (en) Use of no scavengers, inhibitors or antagonists in the treatment of migraine
AU6624996A (en) Use of betaglycan to reduce scarring
IL118491A0 (en) Use of pyrrolidine derivatives in the treatment of alcoholism
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 2000 13170

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 17/2000 UNDER (81) ADD "ZA"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase